VAS 2870 | CAS#722456-31-7 | Nox inhibitor

MedKoo Cat#: 584724 | Name: VAS 2870

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

VAS 2870 is a NADPH oxidase (Nox) inhibitor that enhances TGF-β-induced apoptosis of liver tumor cells.

Chemical Structure

VAS 2870

CAS#722456-31-7

Theoretical Analysis

MedKoo Cat#: 584724

Name: VAS 2870

CAS#: 722456-31-7

Chemical Formula: C18H12N6OS

Exact Mass: 360.0793

Molecular Weight: 360.40

Elemental Analysis: C, 59.99; H, 3.36; N, 23.32; O, 4.44; S, 8.90

Price and Availability

Size	Price	Availability
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,450.00	2 Weeks
1g	USD 3,450.00	2 Weeks
2g	USD 5,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

VAS 2870; VAS2870; VAS-2870

IUPAC/Chemical Name

7-(2-Benzoxazolylthio)-3-(phenylmethyl)-3H-1,2,3-triazolo[4,5-d]pyrimidine

InChi Key

HZSOKHVVANONPV-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H12N6OS/c1-2-6-12(7-3-1)10-24-16-15(22-23-24)17(20-11-19-16)26-18-21-13-8-4-5-9-14(13)25-18/h1-9,11H,10H2

SMILES Code

C12=NC=NC(SC3=NC4=CC=CC=C4O3)=C1N=NN2CC5=CC=CC=C5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 360.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 May;32(4):247-88. doi: 10.1358/mf.2010.32.4.1507200. PMID: 20508873. 2: Kranz H, Gutsche S. Evaluation of the drug release patterns and long term stability of aqueous and organic coated pellets by using blends of enteric and gastrointestinal insoluble polymers. Int J Pharm. 2009 Oct 1;380(1-2):112-9. doi: 10.1016/j.ijpharm.2009.07.013. Epub 2009 Jul 24. PMID: 19632313. 3: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Apr;31(3):183-226. PMID: 19536362. 4: Kranz H, Jürgens K, Pinier M, Siepmann J. Drug release from MCC- and carrageenan-based pellets: experiment and theory. Eur J Pharm Biopharm. 2009 Oct;73(2):302-9. doi: 10.1016/j.ejpb.2009.05.007. Epub 2009 May 22. PMID: 19465119. 5: Tomillero A, Moral MA. Gateways to clinical trials. December 2008. Methods Find Exp Clin Pharmacol. 2008 Dec;30(10):761-82. PMID: 19271026. 6: Tomillero A, Moral MA. Gateways to Clinical Trials. Methods Find Exp Clin Pharmacol. 2008 Nov;30(9):715-24. PMID: 19229381. 7: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. PMID: 19088949. 8: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Apr;30(3):231-51. PMID: 18597009. 9: Lv JL, Wang R, Liu D, Guo G, Jing YK, Zhao LX. Design, synthesis, and antitumor activities of some novel substituted 1,2,3-benzotriazines. Molecules. 2008 Jun 24;13(6):1427-40. doi: 10.3390/molecules13061427. PMID: 18596667; PMCID: PMC6245182. 10: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Dec;29(10):697-735. PMID: 18200333. 11: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83. PMID: 18040531. 12: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):359-73. PMID: 17805439. 13: Yamamoto A, Watanabe H, Sueki H, Nakanishi T, Yasuhara H, Iijima M. Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity. J Dermatol. 2007 Jul;34(7):419-29. doi: 10.1111/j.1346-8138.2007.00304.x. PMID: 17584317. 14: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Apr;29(3):231-45. PMID: 17520107. 15: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jan-Feb;29(1):53-71. PMID: 17344945. 16: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):719-40. PMID: 17235418. 17: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Nov;28(9):657-78. PMID: 17200730. 18: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):451-95. PMID: 17003851. 19: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Mar;28(2):121-42. PMID: 16636723. 20: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 May;26(4):295-318. PMID: 15319808.